Connor, Clark & Lunn Investment Management (CC&L)
JBIO

Connor, Clark & Lunn Investment Management (CC&L)’s Jade Biosciences JBIO Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.83M Buy
217,157
+48,106
+28% +$1M 0.01% 743
2026
Q1 		$2.38M Buy
169,051
+101,821
+151% +$1.47M 0.01% 909
2025
Q4 		$1.04M Buy
+67,230
New +$789K ﹤0.01% 1118

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s JBIO Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Jade Biosciences (JBIO) stake by 28% in Q2 2026, buying an estimated $1M and bringing the position to 217,157 shares worth $4.83M. The position accounts for 0.01% of the portfolio, ranked #743.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in JBIO in Q4 2025 and has held it in 3 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 217,157 shares of Jade Biosciences worth $4.83M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 48,106 Jade Biosciences shares in Q2 2026, an estimated $1M.
  • Jade Biosciences made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #743 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Jade Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.